A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Abaloparatide (Primary)
- Indications Male osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms ATOM
- Sponsors Radius Health Inc.
- 10 May 2018 According to Radius media release, if this study is successful, the data will form the basis of a supplemental NDA seeking to expand TYMLOS label.
- 30 Mar 2018 Status changed from planning to recruiting, according to a Radius Health media release.
- 21 Nov 2017 New trial record